Autoimmune epilepsy

Seminars in Neurology

Volumn 35, Issue 3, 2015, Pages 245-258

  Toledano, Michel ^a   Pittock, Sean J ^a  

^a MAYO CLINIC   (United States)

Author keywords

antibodies; autoimmune; epilepsy; inflammation

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR; AMPA RECEPTOR; AMPHIPHYSIN; ANTICONVULSIVE AGENT; AUTOANTIBODY; CHLORPHENIRAMINE MALEATE PLUS PHENYLEPHRINE; COLLAPSIN RESPONSE MEDIATOR PROTEIN; COLLAPSIN RESPONSE MEDIATOR PROTEIN 5; CYCLOPHOSPHAMIDE; GLUTAMATE DECARBOXYLASE 65; HU ANTIBODY; IMMUNOGLOBULIN; IONOTROPIC RECEPTOR; MA 1 PROTEIN; MA 2 PROTEIN; METABOTROPIC RECEPTOR 5; METHYLPREDNISOLONE; NICOTINIC RECEPTOR; NUCLEAR PROTEIN; RITUXIMAB; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL; NERVE PROTEIN;

ANTICONVULSANT ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE EPILEPSY; AUTOIMMUNITY; BRAIN SCINTISCANNING; CANCER SCREENING; CD8+ T LYMPHOCYTE; CLINICAL FEATURE; CYTOTOXIC T LYMPHOCYTE; EPILEPSY; HUMAN; IMMUNOTHERAPY; LONG TERM CARE; NERVE CELL; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; SEIZURE; COMPLICATION; IMMUNOLOGY; METABOLISM; PARANEOPLASTIC NEUROPATHY; PARANEOPLASTIC SYNDROME;

AUTOANTIBODIES; AUTOIMMUNE DISEASES; AUTOIMMUNITY; EPILEPSY; HUMANS; LIMBIC ENCEPHALITIS; NERVE TISSUE PROTEINS; PARANEOPLASTIC SYNDROMES;

EID: 84930938202     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0035-1552625     Document Type: Article

References (108)

1. McKeon A., Pittock S. J. Paraneoplastic encephalomyelopathies: pathology and mechanisms. Acta Neuropathol: 2011; 122 4 381 400
2. Vincent A., Bien C. G., Irani S. R., Waters P. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol: 2011; 10 8 759 772
3. Lancaster E., Martinez-Hernandez E., Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology: 2011; 77 2 179 189
4. Wilkinson P. C., Zeromski J. Immunofluorescent detection of antibodies against neurones in sensory carcinomatous neuropathy. Brain: 1965; 88 3 529 583
5. Darnell R. B., Posner J. B. Paraneoplastic syndromes involving the nervous system. N Engl J Med: 2003; 349 16 1543 1554
6. Albert M. L., Darnell J. C., Bender A., Francisco L. M., Bhardwaj N., Darnell R. B. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med: 1998; 4 11 1321 1324
7. Tanaka M., Tanaka K., Tokiguchi S., Shinozawa K., Tsuji S. Cytotoxic T cells against a peptide of Yo protein in patients with paraneoplastic cerebellar degeneration and anti-Yo antibody. J Neurol Sci: 1999; 168 1 28 31
8. Dalakas M. C. The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies. J Neurol: 2005; 252 1 01 I19 I25
9. McKeon A., Martinez-Hernandez E., Lancaster E., et al. Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. JAMA Neurol: 2013; 70 1 44 50
10. Kwan P., Schachter S. C., Brodie M. J. Drug-resistant epilepsy. N Engl J Med: 2011; 365 10 919 926
11. Low N. L. Infantile spasms with mental retardation. II. Treatment with cortisone and adrenocorticotropin. Pediatrics: 1958; 22 6 1165 1169
12. Sinclair D. B. Prednisone therapy in pediatric epilepsy. Pediatr Neurol: 2003; 28 3 194 198
13. Sinclair D. B., Snyder T. J. Corticosteroids for the treatment of Landau-Kleffner syndrome and continuous spike-wave discharge during sleep. Pediatr Neurol: 2005; 32 5 300 306
14. Rasmussen T., Olszewski J., Lloydsmith D. Focal seizures due to chronic localized encephalitis. Neurology: 1958; 8 6 435 445
15. Bien C. G., Granata T., Antozzi C., et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain: 2005; 128 Pt 3 454 471
16. Heida J. G., Moshé S. L., Pittman Q. J. The role of interleukin-1beta in febrile seizures. Brain Dev: 2009; 31 5 388 393
17. Ong M. S., Kohane I. S., Cai T., Gorman M. P., Mandl K. D. Population-level evidence for an autoimmune etiology of epilepsy. JAMA Neurol: 2014; 71 5 569 574
18. Vezzani A., Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia: 2005; 46 11 1724 1743
19. Vezzani A., French J., Bartfai T., Baram T. Z. The role of inflammation in epilepsy. Nat Rev Neurol: 2011; 7 1 31 40
20. Gultekin S. H., Rosenfeld M. R., Voltz R., Eichen J., Posner J. B., Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain: 2000; 123 Pt 7 1481 1494
21. Majoie H. J., de Baets M., Renier W., Lang B., Vincent A. Antibodies to voltage-gated potassium and calcium channels in epilepsy. Epilepsy Res: 2006; 71 2-3 135 141
22. Barajas R. F., Collins D. E., Cha S., Geschwind M. D. Adult-onset drug-refractory seizure disorder associated with anti-voltage-gated potassium-channel antibody. Epilepsia: 2010; 51 3 473 477
23. Dalmau J., Lancaster E., Martinez-Hernandez E., Rosenfeld M. R., Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol: 2011; 10 1 63 74
24. Lai M., Hughes E. G., Peng X., et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol: 2009; 65 4 424 434
25. Lancaster E., Lai M., Peng X., et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol: 2010; 9 1 67 76
26. Lancaster E., Martinez-Hernandez E., Titulaer M. J., et al. Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology: 2011; 77 18 1698 1701
27. Peltola J., Kulmala P., Isojärvi J., et al. Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology: 2000; 55 1 46 50
28. Quek A. M., Britton J. W., McKeon A., et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol: 2012; 69 5 582 593
29. Liimatainen S., Peltola M., Sabater L., et al. Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy. Epilepsia: 2010; 51 5 760 767
30. Toledano M., Britton J. W., McKeon A., et al. Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology: 2014; 82 18 1578 1586
31. Suleiman J., Brilot F., Lang B., Vincent A., Dale R. C. Autoimmune epilepsy in children: case series and proposed guidelines for identification. Epilepsia: 2013; 54 6 1036 1045
32. Zuliani L., Graus F., Giometto B., Bien C., Vincent A. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry: 2012; 83 6 638 645
33. Iorio R., Lennon V. A. Neural antigen-specific autoimmune disorders. Immunol Rev: 2012; 248 1 104 121
34. Lucchinetti C. F., Kimmel D. W., Lennon V. A. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology: 1998; 50 3 652 657
35. Roberts W. K., Deluca I. J., Thomas A., et al. Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells. J Clin Invest: 2009; 119 7 2042 2051
36. Graus F., Cordon-Cardo C., Posner J. B. Neuronal antinuclear antibody in sensory neuronopathy from lung cancer. Neurology: 1985; 35 4 538 543
37. Lawn N. D., Westmoreland B. F., Kiely M. J., Lennon V. A., Vernino S. Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc: 2003; 78 11 1363 1368
38. Rudzinski L. A., Pittock S. J., McKeon A., Lennon V. A., Britton J. W. Extratemporal EEG and MRI findings in ANNA-1 (anti-Hu) encephalitis. Epilepsy Res: 2011; 95 3 255 262
39. Dalmau J., Gultekin H. S., Posner J. B. Paraneoplastic neurologic syndromes: pathogenesis and physiopathology. Brain Pathol: 1999; 9 2 275 284
40. Jean W. C., Dalmau J., Ho A., Posner J. B. Analysis of the IgG subclass distribution and inflammatory infiltrates in patients with anti-Hu-associated paraneoplastic encephalomyelitis. Neurology: 1994; 44 1 140 147
41. Bernal F., Graus F., Pifarré A., Saiz A., Benyahia B., Ribalta T. Immunohistochemical analysis of anti-Hu-associated paraneoplastic encephalomyelitis. Acta Neuropathol: 2002; 103 5 509 515
42. Dalmau J., Gultekin S. H., Voltz R., et al. Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain: 1999; 122 Pt 1 27 39
43. Voltz R., Gultekin S. H., Rosenfeld M. R., et al. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med: 1999; 340 23 1788 1795
44. Schmidt E. F., Strittmatter S. M. The CRMP family of proteins and their role in Sema3A signaling. Adv Exp Med Biol: 2007; 600 1 11
45. Arimura N., Hattori A., Kimura T., et al. CRMP-2 directly binds to cytoplasmic dynein and interferes with its activity. J Neurochem: 2009; 111 2 380 390
46. Yu Z., Kryzer T. J., Griesmann G. E., Kim K., Benarroch E. E., Lennon V. A. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol: 2001; 49 2 146 154
47. Cross S. A., Salomao D. R., Parisi J. E., et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol: 2003; 54 1 38 50
48. Lichte B., Veh R. W., Meyer H. E., Kilimann M. W. Amphiphysin, a novel protein associated with synaptic vesicles. EMBO J: 1992; 11 7 2521 2530
49. Dropcho E. J. Antiamphiphysin antibodies with small-cell lung carcinoma and paraneoplastic encephalomyelitis. Ann Neurol: 1996; 39 5 659 667
50. Pittock S. J., Lucchinetti C. F., Parisi J. E., et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol: 2005; 58 1 96 107
51. Wessig C., Klein R., Schneider M. F., Toyka K. V., Naumann M., Sommer C. Neuropathology and binding studies in anti-amphiphysin-associated stiff-person syndrome. Neurology: 2003; 61 2 195 198
52. Geis C., Weishaupt A., Hallermann S., et al. Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition. Brain: 2010; 133 11 3166 3180
53. Lernmark A. Controlling the controls: GAD65 autoreactive T cells in type 1 diabetes. J Clin Invest: 2002; 109 7 869 870
54. Solimena M., Folli F., Denis-Donini S., et al. Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med: 1988; 318 16 1012 1020
55. Solimena M., Folli F., Aparisi R., Pozza G., De Camilli P. Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med: 1990; 322 22 1555 1560
56. Moersch F. P., Woltman H. W. Progressive fluctuating muscular rigidity and spasm (stiff-man syndrome); report of a case and some observations in 13 other cases. Proc Staff Meet Mayo Clin: 1956; 31 15 421 427
57. Pittock S. J., Yoshikawa H., Ahlskog J. E., et al. Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc: 2006; 81 9 1207 1214
58. Bien C. G., Vincent A., Barnett M. H., et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain: 2012; 135 Pt 5 1622 1638
59. Dalakas M. C., Fujii M., Li M., Lutfi B., Kyhos J., McElroy B. High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med: 2001; 345 26 1870 1876
60. Vicari A. M., Folli F., Pozza G., et al. Plasmapheresis in the treatment of stiff-man syndrome. N Engl J Med: 1989; 320 22 1499
61. Boronat A., Sabater L., Saiz A., Dalmau J., Graus F. GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology: 2011; 76 9 795 800
62. Benarroch E. E. Potassium channels: brief overview and implications in epilepsy. Neurology: 2009; 72 7 664 669
63. Gutman G. A., Chandy K. G., Grissmer S., et al. International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol Rev: 2005; 57 4 473 508
64. Ogawa Y., Oses-Prieto J., Kim M. Y., et al. ADAM22, a Kv1 channel-interacting protein, recruits membrane-associated guanylate kinases to juxtaparanodes of myelinated axons. J Neurosci: 2010; 30 3 1038 1048
65. Oiso S., Takeda Y., Futagawa T., et al. Contactin-associated protein (Caspr) 2 interacts with carboxypeptidase E in the CNS. J Neurochem: 2009; 109 1 158 167
66. Lai M., Huijbers M. G., Lancaster E., et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol: 2010; 9 8 776 785
67. Irani S. R., Alexander S., Waters P., et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain: 2010; 133 9 2734 2748
68. Klein C. J., Lennon V. A., Aston P. A., et al. Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping. JAMA Neurol: 2013; 70 2 229 234
69. Thieben M. J., Lennon V. A., Boeve B. F., Aksamit A. J., Keegan M., Vernino S. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology: 2004; 62 7 1177 1182
70. Tan K. M., Lennon V. A., Klein C. J., Boeve B. F., Pittock S. J. Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology: 2008; 70 20 1883 1890
71. Vincent A., Buckley C., Schott J. M., et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain: 2004; 127 Pt 3 701 712
72. McKeon A., Marnane M., O'connell M., Stack J. P., Kelly P. J., Lynch T. Potassium channel antibody associated encephalopathy presenting with a frontotemporal dementia like syndrome. Arch Neurol: 2007; 64 10 1528 1530
73. Geschwind M. D., Tan K. M., Lennon V. A., et al. Voltage-gated potassium channel autoimmunity mimicking Creutzfeldt-Jakob disease. Arch Neurol: 2008; 65 10 1341 1346
74. Flanagan E. P., McKeon A., Lennon V. A., et al. Autoimmune dementia: clinical course and predictors of immunotherapy response. Mayo Clin Proc: 2010; 85 10 881 897
75. Klein C. J., Lennon V. A., Aston P. A., McKeon A., Pittock S. J. Chronic pain as a manifestation of potassium channel-complex autoimmunity. Neurology: 2012; 79 11 1136 1144
76. Irani S. R., Bien C. G., Lang B. Autoimmune epilepsies. Curr Opin Neurol: 2011; 24 2 146 153
77. Irani S. R., Stagg C. J., Schott J. M., et al. Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain: 2013; 136 Pt 10 3151 3162
78. Diani E., Di Bonaventura C., Mecarelli O., et al. Autosomal dominant lateral temporal epilepsy: absence of mutations in ADAM22 and Kv1 channel genes encoding LGI1-associated proteins. Epilepsy Res: 2008; 80 1 1 8
79. Nobile C., Michelucci R., Andreazza S., Pasini E., Tosatto S. C., Striano P. LGI1 mutations in autosomal dominant and sporadic lateral temporal epilepsy. Hum Mutat: 2009; 30 4 530 536
80. Sagane K., Hayakawa K., Kai J., et al. Ataxia and peripheral nerve hypomyelination in ADAM22-deficient mice. BMC Neurosci: 2005; 6 33
81. Baulac S., Ishida S., Mashimo T., et al. A rat model for LGI1-related epilepsies. Hum Mol Genet: 2012; 21 16 3546 3557
82. Rho J. M., Szot P., Tempel B. L., Schwartzkroin P. A. Developmental seizure susceptibility of kv1.1 potassium channel knockout mice. Dev Neurosci: 1999; 21 3-5 320 327
83. Strauss K. A., Puffenberger E. G., Huentelman M. J., et al. Recessive symptomatic focal epilepsy and mutant contactin-associated protein-like 2. N Engl J Med: 2006; 354 13 1370 1377
84. Gregor A., Albrecht B., Bader I., et al. Expanding the clinical spectrum associated with defects in CNTNAP2 and NRXN1. BMC Med Genet: 2011; 12 106 106
85. Lalic T., Pettingill P., Vincent A., Capogna M. Human limbic encephalitis serum enhances hippocampal mossy fiber-CA3 pyramidal cell synaptic transmission. Epilepsia: 2011; 52 1 121 131
86. Dunstan E. J., Winer J. B. Autoimmune limbic encephalitis causing fits, rapidly progressive confusion and hyponatraemia. Age Ageing: 2006; 35 5 536 537
87. Park D. C., Murman D. L., Perry K. D., Bruch L. A. An autopsy case of limbic encephalitis with voltage-gated potassium channel antibodies. Eur J Neurol: 2007; 14 10 e5 e6
88. Khan N. L., Jeffree M. A., Good C., Macleod W., Al-Sarraj S. Histopathology of VGKC antibody-associated limbic encephalitis. Neurology: 2009; 72 19 1703 1705
89. Kotsenas A. L., Watson R. E., Pittock S. J., et al. MRI findings in autoimmune voltage-gated potassium channel complex encephalitis with seizures: one potential etiology for mesial temporal sclerosis. AJNR Am J Neuroradiol: 2014; 35 1 84 89
90. Pinheiro P. S., Mulle C. Presynaptic glutamate receptors: physiological functions and mechanisms of action. Nat Rev Neurosci: 2008; 9 6 423 436
91. Benarroch E. E. NMDA receptors: recent insights and clinical correlations. Neurology: 2011; 76 20 1750 1757
92. Dalmau J., Gleichman A. J., Hughes E. G., et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol: 2008; 7 12 1091 1098
93. Vitaliani R., Mason W., Ances B., Zwerdling T., Jiang Z., Dalmau J. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol: 2005; 58 4 594 604
94. McCoy B., Akiyama T., Widjaja E., Go C. Autoimmune limbic encephalitis as an emerging pediatric condition: case report and review of the literature. J Child Neurol: 2011; 26 2 218 222
95. Irani S. R., Bera K., Waters P., et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain: 2010; 133 Pt 6 1655 1667
96. Schmitt S. E., Pargeon K., Frechette E. S., Hirsch L. J., Dalmau J., Friedman D. Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology: 2012; 79 11 1094 1100
97. Hughes E. G., Peng X., Gleichman A. J., et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci: 2010; 30 17 5866 5875
98. McKeon A., Lennon V. A., Lachance D. H., Fealey R. D., Pittock S. J. Ganglionic acetylcholine receptor autoantibody: oncological, neurological, and serological accompaniments. Arch Neurol: 2009; 66 6 735 741
99. Lennon V. A., Kryzer T. J., Griesmann G. E., et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med: 1995; 332 22 1467 1474
100. Boronat A., Gelfand J. M., Gresa-Arribas N., et al. Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol: 2013; 73 1 120 128
101. Tobin W. O., Lennon V. A., Komorowski L., et al. DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. Neurology: 2014; 83 20 1797 1803
102. Wada K., Yokotani N., Hunter C., Doi K., Wenthold R. J., Shimasaki S. Differential expression of two distinct forms of mRNA encoding members of a dipeptidyl aminopeptidase family. Proc Natl Acad Sci U S A: 1992; 89 1 197 201
103. Nadal M. S., Ozaita A., Amarillo Y., et al. The CD26-related dipeptidyl aminopeptidase-like protein DPPX is a critical component of neuronal A-type K+ channels. Neuron: 2003; 37 3 449 461
104. Titulaer M. J., McCracken L., Gabilondo I., et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol: 2013; 12 2 157 165
105. McKnight K., Jiang Y., Hart Y., et al. Serum antibodies in epilepsy and seizure-associated disorders. Neurology: 2005; 65 11 1730 1736
106. McKeon A., Lennon V. A., Pittock S. J. Immunotherapy-responsive dementias and encephalopathies. Continuum (Minneap Minn): 2010; 16 (2 Dementia): 80 101
107. McKeon A., Apiwattanakul M., Lachance D. H., et al. Positron emission tomography-computed tomography in paraneoplastic neurologic disorders: systematic analysis and review. Arch Neurol: 2010; 67 3 322 329
108. Hacohen Y., Deiva K., Pettingill P., et al. N-methyl-D-aspartate receptor antibodies in post-herpes simplex virus encephalitis neurological relapse. Mov Disord: 2014; 29 1 90 96